Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2017
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L01ED10
|
| gptkbp:brand |
gptkb:Alunbrig
|
| gptkbp:CASNumber |
1197953-54-0
|
| gptkbp:chemicalFormula |
C29H39ClN7O2P
|
| gptkbp:developer |
gptkb:Takeda_Pharmaceutical_Company
|
| gptkbp:form |
gptkb:tablet
|
| gptkbp:genericName |
gptkb:brigatinib
|
| https://www.w3.org/2000/01/rdf-schema#label |
Alunbrig
|
| gptkbp:indication |
ALK-positive metastatic non-small cell lung cancer
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
ALK inhibitor
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea fatigue hypertension cough pneumonitis |
| gptkbp:target |
gptkb:anaplastic_lymphoma_kinase
|
| gptkbp:usedFor |
gptkb:non-small_cell_lung_cancer
|
| gptkbp:bfsParent |
gptkb:brigatinib
gptkb:Takeda gptkb:Takeda_(Japan) |
| gptkbp:bfsLayer |
6
|